


















Of patients with metastatic cancer 10–
15% suffer from severe pain despite sys-
temic pain therapy with oral opiates and 
non-opiate analgesics [10]. Intervention-
al pain therapy using long-term epidural 
catheters (EC) and neuraxial administra-
tion of local anesthetics (LA) and opiates 
has a better analgesic effect, is associated 
with reduction in some of the side effects 
of oral opiates and improves the quality 
of life in these patients [27].
Materials and methods
A 45-year-old male patient (body weight 
52 kg, height 1.61 m and body mass in-
dex 20 kg m−2) with a recurrent gastric 
adenocarcinoma suffered from severe 
upper quadrant abdominal pain due to 
tumor infiltration into the retroperito-
neal space. The only other relevant fact 
from the medical history was smoking-
related chronic obstructive pulmonary 
disease (COPD). Initially the carcino-
ma was diagnosed as grade pT3pN2M0. 
After surgical excision of the carcino-
ma the patient had been asymptomat-
ic until a recurrence of the tumor was 
found on follow-up computed tomog-
raphy (CT) 1 year later. The patient suf-
fered from upper quadrant abdominal 
pain and the initial analgesia with acet-
aminophen, oral morphine and a corti-
costeroid was inadequate. Subsequent-
ly ethanol neurolysis of the celiac plex-
us was performed, although this also 
failed to improve pain control. A tun-
nelled EC (Tuohy 18-G peridural needle 
and catheter, Perifix, Braun, Melsungen, 
Germany) was placed at thoracic spinal 
level 7/8. The correct location of the EC 
was confirmed by injection of 3 ml lido-
caine 2% with epinephrine (1:200,000) 
and the pin-prick method which result-
ed in a change in thoracic sensory level 
to the pin-prick from 4 to 12. The epidu-
ral infusion was started with a mixture 
of bupivacaine HCl 0.25% and morphine 
HCl 0.005% in a 1,000 ml bag via a por-
table, battery powered electronic pump 
at 6 ml h−1 [39]. The infusion solution 
was prepared from stock solution of bu-
pivacaine by the hospital pharmacy of 
the Kantonsspital Lucerne. The solution 
was adjusted to pH 5.5–6.0 with NaOH. 
The daily administered doses amounted 
to 360 mg bupivacaine HCl and 7.16 mg 
morphine HCl. The daily infusion vol-
ume of the LA mixture was 144 ml. With 
this therapy the patient’s pain severity 








abdominal pain occurred and the patient 
was discharged and treated as an outpa-
tient. However, 3 months later the severi-
ty of the pain increased and infusion con-
centrations were doubled to bupivacaine 
HCl 0.5% and morphine HCl 0.01% and 
the infusion rate halved to 3 ml h−1 (daily 
infusion volume 72 ml); therefore the ad-
ministered total daily dose remained the 
same (bupivacaine HCl 360 mg and mor-
phine HCl 7.13 mg). The patient died 6 
months after initiation of epidural anes-
thesia with the EC still in place. An au-
topsy was performed to examine the spi-
nal canal. The total administered dose 
over 6 months (192 days) amounted to 
69 g of bupivacaine HCl and to 1.37 g of 
morphine HCl. The EC provided effec-
tive pain relief and the patient did not re-
port any adverse neurological symptoms 
or other complications from the epidural 
analgesia during this period. The EC was 
never changed but the catheter insertion 
site was regularly inspected and was free 
from any skin reaction or infection.
Results
The autopsy revealed extensive large 
white crystalline deposits in the epidural 





















































































































These deposits and the reference bu-
pivacaine base (derived from commer-
cial bupivacaine HCl, Schweizerhall, Ba-
sel, Switzerland) were analyzed by infra-
red spectrometry (infrared spectrometer: 
Paragon 500 FT-IR, Perkin Elmer, Schw-
erzenbach, Switzerland). The analysis was 
performed on potassium bromide pellets. 
The spectrum of bupivacaine base derived 
in the pharmacy laboratory from com-
mercial bupivacaine HCl served as the ref-
erence (. Fig. 2).
The spectrum of the crystalline depos-
its is presented in . Fig. 3.
Both spectra in the same picture 
(. Fig. 4) illustrate strong similarities.
The correlation coefficient between 
both spectra was automatically calcu-
lated by the infrared spectrometer and 
showed a high correlation (coefficient 
0.973) which indicated that the crystal-
line deposits could be identified as bupi-
vacaine base.
The spectrum of morphine base de-
rived in the pharmacy laboratory from 
commercial morphine HCl (Hänseler, 
Herisau, Switzerland) served as the refer-
ence (. Fig. 5).
There was no similarity between the 
spectrum of bupivacaine base depos-
its and the spectrum of morphine base 
(. Fig. 6).
No morphine base or morphine HCl 
could be detected either by infrared spec-
trometry or by thin-layer chromatogra-
phy (TLC).
A histological examination was per-
formed and . Fig. 7 gives an overview 
showing the crystalline deposits as a 
bright pink eosinophilic material on the 
left side surrounded by soft tissue and 
mainly by fat tissue (dark pink) on the 
right side.
The soft and fat tissue contained some 
calcified tissue corresponding to splin-
tered bone fragments. Crystals with dou-
ble light refraction could not be seen in 
the polarised light. A detail image of ne-
crotic adipocytes within the crystalline 
material is shown in . Fig. 8. Nerve tis-
sue could not be differentiated from the 
crystalline tissue and was not identified 




Of cancer patients 10–15% fail to achieve 
sufficient analgesia from oral medications 
mainly due to tolerance to the analgesic 
effect of opioids and the occurrence of 
opioid-related side effects following dose 
escalation. At this point interventional 
pain therapy, such as epidural analgesia 
can be introduced with much greater ef-
ficacy [12]. Tissue toxicity to LA has been 
documented in animal studies particular-
ly at higher concentrations [2, 3, 4, 6, 7, 8, 
11, 13, 14, 15, 16, 17, 18, 19, 20, 25, 29, 31, 32, 
33, 34, 37, 38] but seldom observed using 
the recommended clinical concentrations 
in humans [1, 15, 22, 23, 24, 26, 28, 31].
Analgesia provided by LA agents ad-
ministered neuraxially can often be aug-
mented by the addition of adjuvants, such 
as opioids (morphine) and alpha agonists 

















































































LA without supplements have not been 
extensively examined for local tissue dam-
age in humans [31] apart from a few case 
reports [1, 15, 22, 23, 24, 26, 28]. To explain 
the mechanism of tissue toxicity various 
pathophysiological pathways of LA or LA 
mixtures in different human and animal 
tissues, such as skin, soft tissue, muscle 
and neurological tissue are discussed but 
the pathogenesis has not been elucidated 
in detail [1, 13, 19, 20, 29, 32, 33, 34, 35, 36, 
37, 38]. Particularly, only limited informa-
tion is available on the extended epidural 
administration of continuous infusion of 
LA or LA mixtures for weeks and months.
The location of crystalline deposit 
seen at autopsy corresponds to the cath-
eter tip, where the highest concentra-
tion of LA is to be expected. In a similar 
case, bupivacaine morphine deposits were 
found in the soft tissue after catheter dis-
lodgement and epidural analgesia thera-
py of 8 weeks duration [1]. To elucidate 
the mechanism for the formation of bu-
pivacaine base deposits, several consider-
ations must be made: (1) bupivacaine is a 
weak base with pKa 8.05. (2) To provide 
a stable solution the bupivacaine base is 
dissolved in HCl to form the salt bupiva-
caine HCl. To maintain a stable solution 
the pH has to be kept well below the pKa, 
usually between 5.5. and 6.0. (3) When a 
bupivacaine HCl solution is infused the 
body buffering capacity (protein, bicar-
bonate) adjusts the pH close to the physi-
ological range of pH 7.4±0.05 which pre-
disposes bupivacaine HCl to precipitate 
[39]. Contrary to lidocaine the in vitro ti-
tration of bupivacaine to a higher pH is 
very critical and results invariably in pre-
cipitation of the drug [1, 21, 39]. Consid-
ering these facts there are several situa-
tions in which the precipitation of bupi-
vacaine in vivo may arise: (1) the pH of 
the LA solution rapidly changed to a high-
er pH value after infusion into the epidur-
al space. (2) The underlying disease (can-
cer) could have altered the solubility of 
the bupivacaine-morphine solution with 
regard to tissue pH, tissue buffer capac-
ity and protein binding [16]. The cancer 
could have diminished the proportion 
of protein-bound drug and thus made it 
more prone to precipitation. (3) The EC as 
a foreign body in the epidural space could 
serve as a facilitator of precipitation. (4) 
In the second period of pain therapy the 
concentrations were doubled to bupiva-
caine HCl 0.5%, morphine HCl 0.01% 
and the infusion rate halved to 3 ml h−1. 
The lower infusion rate and the higher 
concentration of the drug could possibly 
lead to a more rapid adjustment of the tis-
sue to pH 7.4 thereby favoring precipita-
tion. Taken together, the type of drug, the 
concentration, composition, the physico-
chemical properties of the drug, interac-
tions with human tissue, the interaction 
of the EC as foreign body in human tis-
sue, the speed of infusion into the epidu-
ral space and the long-term administra-
tion of the LA mixture could favor precip-
itation with subsequent tissue damage [1]. 
In this case morphine base or morphine 
HCl in the crystals could not be detect-
ed by infrared spectrometry (because the 
quantity was too small or due to complete 
resorption). In a similar case morphine 
HCl could be demonstrated by chemical 
analysis in such LA mixture deposits [1]. 
Morphine does not alter the pH or solu-
bility of LA mixtures [5, 16]. The stability 
and compatibility of such LA mixtures are 
proven to be safe in infusion systems [5, 
9, 14, 16, 30] and safe when used clinically 































er case report [1] discovered bupivacaine 
deposits with unreactive necrosis in dif-
ferent human tissues (e.g. epidural space, 
skin, subcutaneous tissue, muscle and soft 
tissue) after long-term continuous infu-
sion of bupivacaine-morphine mixtures. 
In this case, the histological examination 
revealed fatty tissue necrosis within the 
bupivacaine deposits. Nerve tissue within 
or outside the deposits could not be iden-
tified. In the formerly published case [1] 
soft tissue necrosis developed after dislo-
cation of the thoracic EC into the para-
spinal space with continued inadvertent 
administration of bupivacaine-morphine 
solution [1]. After removal of the EC the 
same initial thoracic sensory level 4–12 on 
both sides persisted until the patient died 
several weeks later. As the CT scan of the 
thoracic spine showed no signs of myelon 
compression, it can be speculated that this 
terminally-ill patient had paraspinal tis-
sue necrosis with crystalline bupivacaine 
deposits in addition to epidural depos-
its similar to the ones found in this case. 
These deposits could possibly maintain 
segmental analgesia in these patients. A 
nerve tissue damage by long-term epidu-
ral application of LA or LA mixtures can-
not be excluded. If the patient would have 
lived for a longer period and the epidur-
al analgesia continued, it could be specu-
lated that compression of the myelon due 
to crystalline growth or direct toxic effects 
on nerve tissue could occur. To the best of 
the authors’ knowledge, there is present-
ly no information on using imaging tech-
niques to detect similar epidural deposits. 
It is not known how common such small 
deposits are during long-term epidural in-
fusion, whether they are specific for bupi-
































Fig. 6 8 Spectrum of bupivacaine base (upper or violet curve) showing no similarity to the spectrum of 
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